Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totaling 63,921 shares, an increase of 109.1% from the June 30th total of 30,569 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 505,096 shares, the short-interest ratio is presently 0.1 days.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on CHGCY. The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy”.
Read Our Latest Research Report on CHGCY
Chugai Pharmaceutical Stock Performance
Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last issued its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The business had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.71%. On average, analysts anticipate that Chugai Pharmaceutical will post 0.96 EPS for the current fiscal year.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.
Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.
Featured Stories
- Five stocks we like better than Chugai Pharmaceutical
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
